文献速递心律失常

电生理引导无创心脏放射消融治疗室性心动过速的I/II期试验

Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia.
PubMed 文献 · Circulation · 2019-01-01

这项前瞻性I/II期试验纳入19例难治性室性心动过速(VT)或PVC相关心肌病患者,采用电生理引导的无创心脏放射消融,单次25 Gy靶向致心律失常瘢痕区。主要安全终点为90天内治疗相关严重不良事件(2/19,10.5%);VT发作中位数从119次降至3次(P<0.001),17/18可评估患者VT或PVC负荷减少,抗心律失常药物使用从59%降至12%(P=0.008),生活质量部分改善。

要点

  • 无创放射消融可显著减少难治性VT发作,中位VT次数从119降至3(P<0.001)。
  • 90天内治疗相关严重不良事件发生率为10.5%(2/19)。
  • 双联抗心律失常药物使用从59%降至12%(P=0.008),部分生活质量域改善。

核心结论

  • 电生理引导的无创心脏放射消融与室性心律失常负荷显著降低相关,短期风险适中,并减少抗心律失常药物使用、改善生活质量。

研究设计与样本

  • 前瞻性I/II期试验,纳入19例成人难治性VT或PVC相关心肌病患者,单次25 Gy靶向致心律失常瘢痕区,主要安全终点为90天内治疗相关严重不良事件。

主要发现

  • 中位无创消融时间为15.3分钟(范围5.4-32.3)。
  • 90天内2/19例(10.5%)发生治疗相关严重不良事件。
  • VT发作中位数从119次(范围4-292)降至3次(范围0-31;P<0.001),ICD电击和抗心动过速起搏均减少。
  • 17/18例可评估患者VT发作或PVC负荷减少(94%),89%患者VT发作或PVC负荷频率降低75%。
  • 6个月总生存率89%,12个月72%;双联抗心律失常药物使用从59%降至12%(P=0.008);6个月时SF-36的9个域中5个改善。

临床怎么用

  • 对于难治性VT或PVC相关心肌病患者,在标准电生理标测与立体定向体部放疗流程下,可考虑单次25 Gy无创放射消融以降低心律失常负荷。
  • 治疗前需结合无创解剖与电生理成像精准定位致心律失常瘢痕区,并评估短期治疗相关严重不良事件风险。
  • 治疗后可通过植入式除颤器监测VT发作、动态心电图评估PVC负荷,并随访抗心律失常药物使用与生活质量变化。

局限性

  • 样本量小(19例),为单臂前瞻性I/II期试验,缺乏对照。
  • 随访时间有限,总生存数据仅报告至12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Case studies have suggested the efficacy of catheter-free, electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia (VT) using stereotactic body radiation therapy, although prospective data are lacking. METHODS: We conducted a prospective phase I/II trial of noninvasive cardiac radioablation in adults with treatment-refractory episodes of VT or cardiomyopathy related to premature ventricular contractions (PVCs). Arrhythmogenic scar regions were targeted by combining noninvasive anatomic and electric cardiac imaging with a standard stereotactic body radiation therapy workflow followed by delivery of a single fraction of 25 Gy to the target. The primary safety end point was treatment-related serious adverse events in the first 90 days. The primary efficacy end point was any reduction in VT episodes (tracked by indwelling implantable cardioverter defibrillators) or any reduction in PVC burden (as measured by a 24-hour Holter monitor) comparing the 6 months before and after treatment (with a 6-week blanking window after treatment). Health-related quality of life was assessed using the Short Form-36 questionnaire. RESULTS: Nineteen patients were enrolled (17 for VT, 2 for PVC cardiomyopathy). Median noninvasive ablation time was 15.3 minutes (range, 5.4-32.3). In the first 90 days, 2/19 patients (10.5%) developed a treatment-related serious adverse event. The median number of VT episodes was reduced from 119 (range, 4-292) to 3 (range, 0-31; P<0.001). Reduction was observed for both implantable cardioverter defibrillator shocks and antitachycardia pacing. VT episodes or PVC burden were reduced in 17/18 evaluable patients (94%). The frequency of VT episodes or PVC burden was reduced by 75% in 89% of patients. Overall survival was 89% at 6 months and 72% at 12 months. Use of dual antiarrhythmic medications decreased from 59% to 12% ( P=0.008). Quality of life improved in 5 of 9 Short Form-36 domains at 6 months. CONCLUSIONS: Noninvasive electrophysiology-guided cardiac radioablation is associated with markedly reduced ventricular arrhythmia burden with modest short-term risks, reduction in antiarrhythmic drug use, and improvement in quality of life. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT02919618.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Robinson CG, Samson PP, Moore KMS, et al. Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia. Circulation. 2019. PMID: 30586734. doi:10.1161/CIRCULATIONAHA.118.038261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。